


ETCTN Trials by Disease/Treatment Area: Lymphoma



NOTE: ▼ Limited trial; not open ETCTN-wide.

## ETCTN Lymphoma Trials (Open as of 5/14/2026)

<b>Protocol Number</b>	<b>Phase</b>	<b>Protocol Title</b>
<b>10299</b>	I	A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients
<b>10335</b>	I	A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)
<b>10508</b>	I/II	A Phase 1 Study of Nivolumab in Combination with ASTX727 in B-cell Lymphoma (NHL or HL) with an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin lymphoma (HL)
<b>10590</b>	II	A Phase 2 Study of Mosunetuzumab or Rituximab in Nodular Lymphocyte-Predominant Hodgkin Lymphoma
<b>10601</b>	I	A Phase 1 Study of Mosunetuzumab with Polatuzumab Vedotin and Lenalidomide (M+Pola+Len) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
<b>10637</b>	II	Phase 2 Trial of Venetoclax in Classic or Variant Hairy Cell Leukemia
<b>10664</b>	Ib	Phase 1b Study of Combination Tovorafenib and Rituximab Treatment in Relapsed or Refractory Classical Hairy Cell Leukemia and Phase 2 Randomized Study Comparing Tovorafenib and Rituximab with Cladribine and Rituximab for Front-Line Treatment of Classical Hairy Cell Leukemia
<b>10702</b>	II	A Phase II Study of Glofitamab for Relapsed/Refractory Mantle Cell Lymphoma in Patients Previously Treated with CD19-Directed CAR T-Cell Therapy
<b>10717</b>	Ib/II	Phase 1b/2 Trial of Pidnarulex in MYC Aberrant Lymphoma
<b>10727</b>	Ib	Phase 1b study of teclistamab in relapsed/refractory plasmablastic lymphoma
<b>10760</b>	I	A Phase I Study of Glofitamab with Alternating R-CHOP/R-DHAP in Previously Untreated Mantle Cell Lymphoma